DiaMedica Issues Stock Option Grants

MINNEAPOLIS, April 17, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX-V: DMA) (OTCQB: DMCAF), today announced the issuance of 2,551,000 stock options to various officers and directors of the Company.  The options were issued at $0.56 per share and have a ten-year term.

The options were granted under the Company's Stock Option Plan and are part of the Company's long term incentive/retention plan for employees. The option issuance is subject to the approval of the TSX Venture Exchange.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and on the OTCQB under the trading symbol “DMCAF”. For more information, please visit www.diamedica.com. Follow us on social media – Twitter, LinkedIn.

Contact:

Paul Papi Vice President of Business Development DiaMedica Therapeutics Inc. Phone: (617) 899-5941 [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.

Source: DiaMedica Therapeutics Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Landis+Gyr Expands Edge Applications Ecosystem with Two New Digital Innovators to Power Next-Generation Intelligent Grid
• Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
• Kyungdong Pharmaceutical and Asimov Announce Completion of Cell Line Development Campaign for Biosimilar Antibody